# Dose Confirmation Efficacy Study (V260-007)

> **NCT00092443** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1312 (actual)

## Conditions studied

- Rotavirus Infections

## Interventions

- **BIOLOGICAL:** RotaTeq™, rotavirus vaccine, live, oral, pentavalent
- **BIOLOGICAL:** Comparator: Placebo matching RotaTeq™

## Key facts

- **NCT ID:** NCT00092443
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 1312 (ACTUAL)
- **Last updated:** 2015-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092443, "Dose Confirmation Efficacy Study (V260-007)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00092443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*